Cointime

Ultragenyx Pharmaceutical

company

About

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

  • 501 - 1000

Highlights

Total Funding Amount
$65M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$65M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2010
Number Of Employee
501 - 1000
Operating Status
Active

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Ultragenyx Pharmaceutical has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on Jun 7, 2016 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 7, 2016 Post-IPO Equity $65M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Ultragenyx Pharmaceutical is funded by 1 investors. Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
Takeda — Post-IPO Equity
Cointime
İçerikler
Şirket.